Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.
Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV.
复制标题
DOI：
10.1097/qad.0000000000002728
复制
发表时间：
2021-01-01
期刊：
影响因子：
--
通讯作者：
French AL
中科院分区：
文献类型：
--
作者：
Serrano PA;Daubert E;Munoz A;Hosek SG;French AL
2019年，美国倡导者报告了针对吉利德科学公司的诉讼广告中使用的关于TDF/FTC （Truvada®）安全性的误导性语言。我们试图确定广告对艾滋病毒感染风险青年和青壮年群体的PrEP意见和决定的影响范围和影响。对参加keep it LITE的参与者进行了一项在线调查，这是一项前瞻性的美国队列研究，研究对象是年龄在13-37岁之间的不同种族、性活跃、顺性和变性人。定量数据采用SAS的描述和推理分析，定性数据采用专题分析。调查回复率为51.3% （n=1485）。基线时的平均年龄为24岁。43%的应答者报告曾使用过PrEP， 32.7%的应答者报告在过去6个月内使用过PrEP。几乎一半（48.7%）的人知道这起诉讼。大多数参与者（81.3%）报告说广告没有影响他们的PrEP使用，但13.2%的人决定不开始基于特鲁瓦达的PrEP方案，5.5%的人决定停止服用特鲁瓦达。改变PrEP行为的预测因素是教育程度较低和以前没有使用过PrEP。定性分析显示，广告增加了对特鲁瓦达PrEP的安全性和益处的怀疑，并导致对制药行业的更大不信任。这些广告吸引了大量不同类型的美国观众。令人不安的是，18.7%知道诉讼的PrEP候选人将未开始或停止基于特鲁瓦达的PrEP方案归因于接触特鲁瓦达诉讼广告。
In 2019, US advocates reported misleading language regarding the safety of TDF/FTC (Truvada®) used by lawsuit advertisements against Gilead Sciences. We sought to ascertain the reach and effects of the advertisements on PrEP opinions and decisions in a cohort of youth and young adults at-risk for HIV. An online survey was administered to participants enrolled in Keeping it LITE, a prospective US cohort study of ethnically diverse, sexually active, cis- and transgender persons ages 13–37. Quantitative data were analyzed using descriptive and inferential analysis in SAS, and qualitative data via thematic analysis. Survey response rate was 51.3% (n=1485). Mean age at baseline was 24. Previous PrEP use was reported by 43% of respondents and 32.7% reported PrEP use in the past 6 months. Almost half (48.7%) were aware of the lawsuit. Most of these participants (81.3%) reported the advertisements did not impact their PrEP use, but 13.2% decided to not to begin a Truvada-based PrEP regimen and 5.5% decided to stop taking Truvada due to the advertisements claims. Predictors of changing PrEP behavior were lower education and no previous PrEP use. The qualitative analysis revealed the advertisements increased skepticism about safety and benefit of Truvada PrEP and led to greater distrust of the pharmaceutical industry. The advertisements reached a large, diverse US audience. Disturbingly, 18.7% of PrEP candidates who were aware of the lawsuit attributed not initiating or cessation of a Truvada-based PrEP regimen to exposure to the Truvada lawsuit advertisements.